I read recently about a new trial to assess whether self-administered moxa on ST36 can reduce chemotherapy-induced pancytopenia, specifically neutropenia, anaemia, and thrombocytopenia, thus enabling patients to complete courses of chemotherapy without delays or dose reduction.
The aim of the researchers is to recruit 25 breast, colorectal, or gynaecological cancer patients to perform this simple… Continue reading